Objective:

To report a unique case of spontaneous lobar intracerebral hemorrhage (ICH) in a patient with advanced hepatocellular carcinoma (HCC) undergoing lenvatinib therapy, particularly in the absence of traditional risk factors, and to review relevant literature.

Approach:

Key Findings:

• The patient experienced a spontaneous lobar ICH after seven months of lenvatinib therapy, a rare occurrence.
• Mild-to-moderate thrombocytopenia was present but insufficient to fully explain the hemorrhage.
• No traditional risk factors for ICH, such as hypertension or structural brain lesions, were identified, underscoring the need for vigilance.

Interpretation:

This case suggests a possible association between lenvatinib therapy and spontaneous ICH, highlighting the need for vigilance in monitoring neurological symptoms during treatment, especially given the rarity of such events.

Limitations:

• The rarity of ICH during lenvatinib therapy limits generalizability.
• The case report does not establish a causal relationship between lenvatinib and ICH, necessitating further studies.

Conclusion:

The report emphasizes the importance of monitoring for neurological symptoms in patients receiving lenvatinib, even in the absence of traditional risk factors, to ensure timely intervention.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.